Anticoagulant drug treatment management follow-up visit system

Abstract

The invention relates to the technical field of medical data processing systems, in particular to an anticoagulant drug treatment management follow-up visit system which comprises a patient basic information data acquisition module, a medication evaluation module, a problem and evaluation module, a medication planning module, a physician end, a pharmacist end and a patient end. By adopting the system provided by the invention, the working efficiency of medical staff is improved, analysis and suggestion are carried out according to the medication condition of the patient, the safety of the patient when the patient uses the anticoagulant drug is enhanced, the medication condition of the patient is standardized, meanwhile, the medical staff can conveniently know the medication condition of the patient in time, and adverse drug events are reduced.

Description

technical field [0001] The invention relates to the technical field of medical data processing systems, in particular to an anticoagulant drug treatment management follow-up system. Background technique [0002] Venous thromboembolism (VTE) includes deep vein thrombosis (DVT) and pulmonary embolism (PE), and while the exact incidence of VTE is unknown, it affects an estimated 1 million people in the U.S. each year, approximately 1 in 3 Recurrence within 10 years. VTE can involve both hospitalized and ambulatory patients and lead to long-term complications, including post-thrombotic syndrome (PTS) of thrombotic DVT, chronic thromboembolic pulmonary hypertension, and death. [0003] With the improvement of medical level, the diagnosis rate of DVT and PE is constantly increasing. In 2019, the Chinese Venous Thrombosis Research Group conducted a large-scale multi-center retrospective study. During the ten years from 2007 to 2016, 90 domestic hospitals According to the statisti...

AI Technical Summary

Problems solved by technology

[0005] The awareness of anticoagulation among medical staff, patients and their families is not strong. In the treatment of patients with venous thromboembolism, non-standard use of anticoagulant drugs and poor compliance of patients will lead to poor anticoagulant treatment effect; The drug warfarin requires regular detection of coagulation indicators such as INR, and requires professionals to guide the administration of warfarin, and warfarin is easily affected by food, other drugs, and patient genes; while new oral anticoagulants have an exact dose-effect relationship , but there are also drug interactions and the influence of liver and kidney function; heparin drugs may cause heparin-induced thrombocytopenia, and in some special cases, it is necessary to investigate anti-factor Xa and adjust the drug dose

Therefore, in general, insufficient or excessive dosage of anticoagulant drugs will cause risks to patients, and long-term follow-up of the safety of anticoagulant drugs is required after patients are discharged from the hospital; Risk of interaction, increased occurrence of adverse drug events

Images